Karen Seibert
- Pharmacology top 0.01%
- Genetics top 0.2%
- Molecular Biology top 2%
- Organic Chemistry top 0.2%
- Biochemistry top 0.02%
- Co-authors
- Jaime L. MasferrerPeter C. IsaksonPhilip NeedlemanBen S. ZweifelScott D. HauserK. LeahyCarol M. KoboldtChinthalapally V. Rao
- Topics
- Inflammatory mediators and NSAID effects (81 papers)Estrogen and related hormone effects (45 papers)Eicosanoids and Hypertension Pharmacology (23 papers)
- Cited by
- PharmacologyBiochemistryGenetics
- Partner nations
- United StatesCanadaAustralia
In The Last Decade
Karen Seibert
97 papers receiving 18.0k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Pharmacology 11.2k
- Genetics 4.5k
- Molecular Biology 3.9k
- Organic Chemistry 3.7k
- Biochemistry 2.9k
Countries citing papers authored by Karen Seibert
This map shows the geographic impact of Karen Seibert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Seibert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Seibert more than expected).
Fields of papers citing papers by Karen Seibert
This network shows the impact of papers produced by Karen Seibert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Seibert. The network helps show where Karen Seibert may publish in the future.
Co-authorship network of co-authors of Karen Seibert
This figure shows the co-authorship network connecting the top 25 collaborators of Karen Seibert. A scholar is included among the top collaborators of Karen Seibert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Seibert. Karen Seibert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 43 | |
| 2 | 28 | |
| 3 | 72 | |
| 4 | Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. | 60 |
| 5 | 86 | |
| 6 | 42 | |
| 7 | 69 | |
| 8 | Aspirin-like molecules that covalently inactivate cyclooxygenase-2 | 50 |
| 9 | 32 | |
| 10 | 118 | |
| 11 | 32 | |
| 12 | 359 | |
| 13 | Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. | 372 |
| 14 | 331 | |
| 15 | Novel 1,2-diarylcyclopentenes are selective, potent, and orally active cyclooxygenase inhibitors | 10 |
| 16 | 121 | |
| 17 | Discovery of a better aspirin. | 21 |
| 18 | 22 | |
| 19 | 5 | |
| 20 | 5 |
About Karen Seibert
Karen Seibert is a scholar working on Pharmacology, Biochemistry and Genetics, having authored 99 papers that have together received 18.8k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (81 papers), Estrogen and related hormone effects (45 papers) and Eicosanoids and Hypertension Pharmacology (23 papers). The work is most often cited by research in Pharmacology (11.2k citations), Biochemistry (2.9k citations) and Genetics (4.5k citations). Karen Seibert has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Jaime L. Masferrer, Peter C. Isakson, Philip Needleman, Ben S. Zweifel, Scott D. Hauser, K. Leahy, Carol M. Koboldt, Chinthalapally V. Rao, Mark G. Currie and James K. Gierse. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.